Matthew B. Klein net worth and biography

Matthew Klein Biography and Net Worth

Director of ClearPoint Neuro

Matthew B. Klein joined our Board in April 2020. Dr. Klein serves as the Chief Executive Officer and President of PTC Therapeutics, Inc., or “PTC”. Dr. Klein joined PTC in October 2019 as Global Head Gene and Mitochondrial Therapies, became Chief Development Officer in April 2020, assumed the role of Chief Operating Officer in January 2022, and became Chief Executive Officer and President in March 2023. Prior to joining PTC, Dr. Klein was Chief Executive Officer and a Director of BioElectron Technology Corporation, or “BioElectron,” from 2018 to 2019. Dr. Klein served as the Chief Medical Officer of BioElectron from 2013 to 2019 and was Senior Vice President, Clinical Science at BioElectron from 2012 to 2013. Dr. Klein has a B.A. from the University of Pennsylvania, an M.D. from Yale University School of Medicine and an M.S. in epidemiology from the University of Washington School of Public Health. We believe that Dr. Klein is qualified to serve on our Board because of his medical background, leadership experience and gene therapy and biopharmaceutical industry expertise.

What is Matthew B. Klein's net worth?: The estimated net worth of Matthew B. Klein is at least $634.56 thousand as of May 21st, 2026. Dr. Klein owns 46,935 shares of ClearPoint Neuro stock worth more than $634,561 as of June 16th. This net worth approximation does not reflect any other assets that Dr. Klein may own. Learn More about Matthew B. Klein's net worth.
How do I contact Matthew B. Klein?: The corporate mailing address for Dr. Klein and other ClearPoint Neuro executives is 5 MUSICK, IRVINE CA, 92618. ClearPoint Neuro can also be reached via phone at (949) 900-6833 and via email at [email protected]. Learn More on Matthew B. Klein's contact information.
Has Matthew B. Klein been buying or selling shares of ClearPoint Neuro?: Within the last three months, Matthew B. Klein has sold $185,440.00 in shares of ClearPoint Neuro stock. Most recently, Matthew B. Klein sold 16,000 shares of the business's stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $11.59, for a transaction totalling $185,440.00. Following the completion of the sale, the director now directly owns 46,935 shares of the company's stock, valued at $543,976.65. Learn More on Matthew B. Klein's trading history.
Who are ClearPoint Neuro's active insiders?: ClearPoint Neuro's insider roster includes Joseph Burnett (CEO), Joseph Burnett (President & CEO), Lynnette Fallon (Director), Matthew Klein (Director), and Timothy Richards (Director). Learn More on ClearPoint Neuro's active insiders.
Are insiders buying or selling shares of ClearPoint Neuro?: During the last year, insiders at the sold shares 6 times. They sold a total of 75,912 shares worth more than $1,390,248.54. The most recent insider tranaction occured on June, 1st when Director Timothy T Richards sold 5,415 shares worth more than $65,900.55. Insiders at ClearPoint Neuro own 6.9% of the company. Learn More about insider trades at ClearPoint Neuro.
Information on this page was last updated on 6/1/2026.

Matthew B. Klein Insider Trading History at ClearPoint Neuro

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/21/2026	Sell	16,000	$11.59	$185,440.00	46,935

Matthew B. Klein Buying and Selling Activity at ClearPoint Neuro

ClearPoint Neuro Company Overview

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Today's Range

Now: $13.38

$13.32

$13.74

50 Day Range

MA: $11.58

$8.68

$14.32

2 Week Range

Now: $13.38

$8.27

$30.10

Volume

82,690 shs

Average Volume

693,781 shs

Market Capitalization

$401.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31